These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 14974883)

  • 1. [Chronic hepatitis C drug therapy update].
    Ruano Camps R; Gallego Fernández C
    Farm Hosp; 2003; 27(6):371-85. PubMed ID: 14974883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic hepatitis C virus management: 2000-2005 update.
    Hughes CA; Shafran SD
    Ann Pharmacother; 2006 Jan; 40(1):74-82. PubMed ID: 16368925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatitis C virus: the first decade.
    Poynard T
    Semin Liver Dis; 2004; 24 Suppl 2():19-24. PubMed ID: 15346242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ribavirin plus interferon-alpha in patients aged >or=60 years with chronic hepatitis C.
    Honda T; Katano Y; Urano F; Murayama M; Hayashi K; Ishigami M; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2007 Jul; 22(7):989-95. PubMed ID: 17608843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retreatment of patients with chronic hepatitis C].
    Ostojić R
    Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of chronic hepatitis C treatment in hemophilic patients.
    Husa P; Roznovsky L; Smejkal P; Husova L; Penka M; Dite P
    Hepatogastroenterology; 2005; 52(65):1541-4. PubMed ID: 16201114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
    Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
    J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C virus infection in children.
    Mohan N; González-Peralta RP; Fujisawa T; Chang MH; Heller S; Jara P; Kelly D; Mieli-Vergani G; Shah U; Murray KF
    J Pediatr Gastroenterol Nutr; 2010 Feb; 50(2):123-31. PubMed ID: 20038846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost evaluation of therapeutic management of patients with chronic hepatitis C].
    Faure C; Gasser P; Douet MC
    Therapie; 1997; 52(6):553-8. PubMed ID: 9734107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of combined therapy in chronic hepatitis C].
    Casado MA; Buti M; Fosbrook L; Esteban R
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.
    Ramos-Casals M; Trejo O; García-Carrasco M; Font J
    Rheumatology (Oxford); 2003 Jul; 42(7):818-28. PubMed ID: 12730523
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic hepatitis C. Treatment and side effect management.
    Lee SP
    Adv Nurse Pract; 2003 Jul; 11(7):73-8. PubMed ID: 12886741
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
    Girardin F; Goossens N; Vernaz N; Negro F
    Rev Med Suisse; 2015 Sep; 11(484):1610-2, 1614-6. PubMed ID: 26502622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healing livers, saving lives: Hepatitis C screening in an era of cure.
    Boucher CM; Walsh A; Forest CP
    JAAPA; 2016 May; 29(5):20-8. PubMed ID: 27049400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.